COVID-19 and Its Implications for Thrombosis and Anticoagulation

Author:

Berkman Samuel A.1,Tapson Victor F.2

Affiliation:

1. Department of Medicine, University of California Los Angeles, Hematology/Oncology, Los Angeles, California

2. Department of Medicine, Cedars Sinai Medical Center, Los Angeles, California

Abstract

AbstractVenous thromboembolism, occlusion of dialysis catheters, circuit thrombosis in extracorporeal membrane oxygenation (ECMO) devices, acute limb ischemia, and isolated strokes, all in the face of prophylactic and even therapeutic anticoagulation, are features of novel coronavirus disease 2019 (COVID-19) coagulopathy. It seems well established at this time that a COVID-19 patient deemed sick enough to be hospitalized, should receive at least prophylactic dose anticoagulation. However, should some hospitalized patients have dosage escalation to intermediate dose? Should some be considered for full-dose anticoagulation without a measurable thromboembolic event and how should that anticoagulation be monitored? Should patients receive postdischarge anticoagulation and with what medication and for how long? What thrombotic issues are related to the various medications being used to treat this coagulopathy? Is antiphospholipid antibody part of this syndrome? What is the significance of isolated ischemic stroke and limb ischemia in this disorder and how does this interface with the rest of the clinical and laboratory features of this disorder? The aims of this article are to explore these questions and interpret the available data based on the current evidence.

Publisher

Georg Thieme Verlag KG

Subject

Critical Care and Intensive Care Medicine,Pulmonary and Respiratory Medicine

Reference76 articles.

1. Pandemic H1N1 influenza infection and vascular thrombosis;P E Bunce;Clin Infect Dis,2011

2. Thromboembolic events in patients with severe pandemic influenza A/H1N1;L S Avnon;Eur J Intern Med,2015

3. Analysis of deaths during the severe acute respiratory syndrome (SARS) epidemic in Singapore: challenges in determining a SARS diagnosis;P Y Chong;Arch Pathol Lab Med,2004

4. Acute respiratory distress syndrome in critically ill patients with severe acute respiratory syndrome;T WK Lew;JAMA,2003

5. State of knowledge and data gaps of Middle East respiratory syndrome coronavirus (MERS-CoV) in humans;Who Mers-Cov Research Group;PLoS Curr,2013

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3